FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITOR-PILOT)

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506550-20-00

Enrollment

Registered

2024-03-25

Start date

2024-07-05

Completion date

2025-10-30

Last updated

2025-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic breast cancer

Brief summary

Overall survival

Detailed description

Quality of life, Time and exposure to treatment, Cost-effectiveness, Occurrence of adverse events

Interventions

DRUGFLUDEOXYGLUCOSE (18F)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Quality of life, Time and exposure to treatment, Cost-effectiveness, Occurrence of adverse events	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026